A phase 1 trial of the MEK inhibitor selumetinib in combination with pembrolizumab for advanced or metastatic solid tumors
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
A phase 1 trial of the MEK inhibitor selumetinib in combination with pembrolizumab for advanced or metastatic solid tumors ; day:14 ; month:3 ; year:2024 ; pages:1-11
Investigational new drugs ; (14.3.2024), 1-11
- Creator
-
Chénard-Poirier, Maxime
Hansen, Aaron R.
Gutierrez, Martin E.
Rasco, Drew
Xing, Yan
Chen, Lin-Chi
Zhou, Heng
Webber, Andrea L.
Freshwater, Tomoko
Sharma, Manish R.
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s10637-024-01428-0
- URN
-
urn:nbn:de:101:1-2405162108485.683430160053
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 11:00 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Chénard-Poirier, Maxime
- Hansen, Aaron R.
- Gutierrez, Martin E.
- Rasco, Drew
- Xing, Yan
- Chen, Lin-Chi
- Zhou, Heng
- Webber, Andrea L.
- Freshwater, Tomoko
- Sharma, Manish R.
- SpringerLink (Online service)
Other Objects (12)
Abemaciclib in combination with pembrolizumab for HR+, HER2− metastatic breast cancer: Phase 1b study
Objective Responses in Metastatic Pleomorphic Rhabdomyosarcoma Treated with Combination of Doxorubicin and Pembrolizumab: A Case Series
MEK targeting in N-RAS mutated metastatic melanoma
Pembrolizumab as first-line treatment for metastatic uveal melanoma
Combination therapy of KRAS G12V mRNA vaccine and pembrolizumab: clinical benefit in patients with advanced solid tumors
Combination Therapy of Pembrolizumab plus Axitinib for a Patient on Hemodialysis with Metastatic Renal Cell Carcinoma: A Case Report
BRAFV600E mutation positive metastatic melanoma in a young woman treated with anti-BRAF/anti MEK combination: a case report
KRAS4A and KRAS4B in liquid biopsy of metastatic lung adenocarcinoma patients treated with Pembrolizumab or chemotherapy plus Pembrolizumab
Pembrolizumab
Correction to: CXCR2 antagonist navarixin in combination with pembrolizumab in select advanced solid tumors: a phase 2 randomized trial
Near complete response to Pembrolizumab in microsatellite-stable metastatic sebaceous carcinoma
..mek
Abemaciclib in combination with pembrolizumab for HR+, HER2− metastatic breast cancer: Phase 1b study
Objective Responses in Metastatic Pleomorphic Rhabdomyosarcoma Treated with Combination of Doxorubicin and Pembrolizumab: A Case Series
MEK targeting in N-RAS mutated metastatic melanoma
Pembrolizumab as first-line treatment for metastatic uveal melanoma
Combination therapy of KRAS G12V mRNA vaccine and pembrolizumab: clinical benefit in patients with advanced solid tumors
Combination Therapy of Pembrolizumab plus Axitinib for a Patient on Hemodialysis with Metastatic Renal Cell Carcinoma: A Case Report
BRAFV600E mutation positive metastatic melanoma in a young woman treated with anti-BRAF/anti MEK combination: a case report
KRAS4A and KRAS4B in liquid biopsy of metastatic lung adenocarcinoma patients treated with Pembrolizumab or chemotherapy plus Pembrolizumab
Pembrolizumab
Correction to: CXCR2 antagonist navarixin in combination with pembrolizumab in select advanced solid tumors: a phase 2 randomized trial
Near complete response to Pembrolizumab in microsatellite-stable metastatic sebaceous carcinoma
..mek
Abemaciclib in combination with pembrolizumab for HR+, HER2− metastatic breast cancer: Phase 1b study
Objective Responses in Metastatic Pleomorphic Rhabdomyosarcoma Treated with Combination of Doxorubicin and Pembrolizumab: A Case Series
MEK targeting in N-RAS mutated metastatic melanoma
Pembrolizumab as first-line treatment for metastatic uveal melanoma
Combination therapy of KRAS G12V mRNA vaccine and pembrolizumab: clinical benefit in patients with advanced solid tumors
Combination Therapy of Pembrolizumab plus Axitinib for a Patient on Hemodialysis with Metastatic Renal Cell Carcinoma: A Case Report
BRAFV600E mutation positive metastatic melanoma in a young woman treated with anti-BRAF/anti MEK combination: a case report
KRAS4A and KRAS4B in liquid biopsy of metastatic lung adenocarcinoma patients treated with Pembrolizumab or chemotherapy plus Pembrolizumab
Pembrolizumab
Correction to: CXCR2 antagonist navarixin in combination with pembrolizumab in select advanced solid tumors: a phase 2 randomized trial
Near complete response to Pembrolizumab in microsatellite-stable metastatic sebaceous carcinoma